Bortezomib has little ex vivo activity in chronic myeloid leukemia: individual tumor response testing comparative study in acute and chronic myeloid leukemia

AIM OF THE STUDY: Resistance to imatinib is one of the most important issues in treatment of chronic myeloid leukemia (CML) patients. The objective of the study was to analyze the ex vivo drug resistance profile to bortezomib and 22 other antileukemic drugs, including three tyrosine kinase inhibitor...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Styczyński, Jan, Gil, Lidia, Czyżewski, Krzysztof, Kołodziej, Beata, Kuryło-Rafińska, Beata, Lewandowski, Krzysztof, Gniot, Michał, Lewandowska, Maria, Komarnicki, Mieczysław, Wysocki, Mariusz
Formato: Artigo
Idioma:Inglês
Publicado: Termedia Publishing House 2012
Assuntos:
Original Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3687416/
https://ncbi.nlm.nih.gov/pubmed/23788881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2012.29286
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares